Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
The effects of N-2-(p-chlorophenoxy)-isobutyryl-N'-morpholinomethylurea (plafibride, ITA 104) were studied in a trial under double which an increase in thromboembolic risk is suspected, either associated with, or secondary to, the actual atherosclerotic disease.